使用基因表达谱对 T1-T2 期黑色素瘤患者的前哨淋巴结活检决策进行指导。
Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.
机构信息
Division of Surgical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Department of Surgery, St Louis University, St Louis, MO 63110, USA.
出版信息
Future Oncol. 2019 Apr;15(11):1207-1217. doi: 10.2217/fon-2018-0912. Epub 2019 Jan 29.
AIM
Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity?
PATIENTS & METHODS: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively.
RESULTS
Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4.9% and 1.6%. Class 2B (high-risk) patients had SLN positivity rates of 30.8% and 11.9%. Melanoma-specific survival was 99.3% for patients ≥55 years with class 1A, T1-T2 tumors and 55.0% for class 2B, SLN-positive, T1-T2 tumors.
CONCLUSION
The 31-gene expression profile test identifies patients who could potentially avoid SLN biopsy.
目的
基因表达谱分析能否用于识别 T1-T2 期黑色素瘤患者中 SLN 阳性率低的患者？
患者与方法
生物信息学模型确定了一个人群，其中 31 个基因表达谱测试预测 SLN 阳性率<5%。前瞻性测试（n=1421）和回顾性（n=690）队列分别用于验证和结局。
结果
55-64 岁和≥65 岁的 1A 级（低危）患者的 SLN 阳性率分别为 4.9%和 1.6%。2B 级（高危）患者的 SLN 阳性率分别为 30.8%和 11.9%。≥55 岁、1A 级、T1-T2 肿瘤患者的黑色素瘤特异性生存率为 99.3%，而 2B 级、SLN 阳性、T1-T2 肿瘤患者的黑色素瘤特异性生存率为 55.0%。
结论
31 个基因表达谱测试可以识别出那些可能可以避免 SLN 活检的患者。
Zotero 插件